Show simple item record

dc.contributor.authorCrusz, SMen_US
dc.contributor.authorTang, YZen_US
dc.contributor.authorSarker, S-Jen_US
dc.contributor.authorPrevoo, Wen_US
dc.contributor.authorKiyani, Ien_US
dc.contributor.authorBeltran, Len_US
dc.contributor.authorPeters, Jen_US
dc.contributor.authorSahdev, Aen_US
dc.contributor.authorBex, Aen_US
dc.contributor.authorPowles, Ten_US
dc.contributor.authorGerlinger, Men_US
dc.date.accessioned2017-01-10T09:53:01Z
dc.date.available2016-10-26en_US
dc.date.issued2016-11-14en_US
dc.date.submitted2017-01-04T09:22:06.214Z
dc.identifier.issn1741-7015en_US
dc.identifier.otherARTN 185en_US
dc.identifier.otherARTN 185en_US
dc.identifier.otherARTN 185en_US
dc.identifier.otherARTN 185en_US
dc.identifier.otherARTN 185en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/18456
dc.descriptionSC was funded by fellowships from NIHR and Cancer Research UK. IK was funded by the UCLH Experimental Cancer Centre and UCLH NIHR Biomedical Research Centre. TP was funded by grants from Cancer Research UK (the Experimental Cancer Medicine Centre). MG was funded by grants from Cancer Research UK, Prostate Cancer UK, the Prostate Cancer Foundation, the Schottlander Research Charitable Trust, the Royal Marsden NIHR Biomedical Research Centre for Cancer and the Wellcome Trust (grant number: 105104/Z/14/Z)en_US
dc.language.isoenen_US
dc.relation.ispartofBMC MEDICINEen_US
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
dc.subjectAnti-angiogenic treatmenten_US
dc.subjectDrug resistanceen_US
dc.subjectIntratumour heterogeneityen_US
dc.subjectKidney canceren_US
dc.subjectRECISTen_US
dc.titleHeterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinomaen_US
dc.typeArticle
dc.rights.holder(c) The Authors, 2016
dc.identifier.doi10.1186/s12916-016-0729-9en_US
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387729800002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume14en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record